(VIANEWS) – Eli Lilly and Company (LLY), Arthur J. Gallagher & Co. (AJG), Align Technology (ALGN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Eli Lilly and Company (LLY)
17.3% sales growth and 65.6% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $7.2.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 84.43. Meaning, the purchaser of the share is investing $84.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 65.6%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 13, 2023, the estimated forward annual dividend rate is 4.52 and the estimated forward annual dividend yield is 0.83%.
Sales Growth
Eli Lilly and Company’s sales growth is 17% for the ongoing quarter and 17.3% for the next.
Previous days news about Eli Lilly and Company(LLY)
- According to Zacks on Thursday, 12 October, "Shares of Eli Lilly and Company (LLY Quick QuoteLLY – Free Report) were up almost 5% on Wednesday after rival Novo Nordisk (NVO Quick QuoteNVO – Free Report) announced that a kidney outcomes study on its diabetes medicine Ozempic (semaglutide) was being stopped earlier than planned due to efficacy."
2. Arthur J. Gallagher & Co. (AJG)
16.3% sales growth and 11.55% return on equity
Arthur J. Gallagher & Co., together with its subsidiaries, provides insurance and reinsurance brokerage, consulting, and third-party property/casualty claims settlement and administration services to businesses and organizations worldwide. It operates in Brokerage and Risk Management segments. The Brokerage segment offers retail and wholesale insurance and reinsurance brokerage services; assists retail brokers and other non-affiliated brokers in the placement of specialized and hard-to-place insurance; and acts as a brokerage wholesaler, managing general agent, and managing general underwriter for distributing specialized insurance coverages to underwriting enterprises. This segment also performs activities, including marketing, underwriting, issuing policies, collecting premiums, appointing and supervising other agents, paying claims, and negotiating reinsurance; and offers services in the areas of insurance and reinsurance placement, risk of loss management, and management of employer sponsored benefit programs. The Risk Management segment provides contract claim settlement and administration services; and claims management, loss control consulting, and insurance property appraisal services. The company offers its services through a network of correspondent brokers and consultants. It serves commercial, industrial, public, religious, and not-for-profit entities, as well as underwriting enterprises. The company was founded in 1927 and is headquartered in Rolling Meadows, Illinois.
Earnings Per Share
As for profitability, Arthur J. Gallagher & Co. has a trailing twelve months EPS of $5.11.
PE Ratio
Arthur J. Gallagher & Co. has a trailing twelve months price to earnings ratio of 45.74. Meaning, the purchaser of the share is investing $45.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.55%.
3. Align Technology (ALGN)
14.6% sales growth and 8.68% return on equity
Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, China, and internationally. It operates in two segments, Clear Aligner; and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; and non-case products that include retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment. The Systems and Services segment offers iTero intraoral scanning system, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, and pay per scan services Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
Earnings Per Share
As for profitability, Align Technology has a trailing twelve months EPS of $4.07.
PE Ratio
Align Technology has a trailing twelve months price to earnings ratio of 65.17. Meaning, the purchaser of the share is investing $65.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.68%.
Previous days news about Align Technology(ALGN)
- According to Zacks on Friday, 13 October, "Some better-ranked stocks in the broader medical space are Align Technology (ALGN Quick QuoteALGN – Free Report) , McKesson Corporation (MCK Quick QuoteMCK – Free Report) and Medpace (MEDP Quick QuoteMEDP – Free Report) ."
- According to Zacks on Thursday, 12 October, "Some better-ranked stocks in the broader medical space are Cardinal Health (CAH Quick QuoteCAH – Free Report) , Haemonetics (HAE Quick QuoteHAE – Free Report) and Align Technology (ALGN Quick QuoteALGN – Free Report) , each carrying a Zacks Rank #2 (Buy). "
- According to Zacks on Thursday, 12 October, "Some better-ranked stocks in the broader medical space are Align Technology (ALGN Quick QuoteALGN – Free Report) , McKesson Corporation (MCK Quick QuoteMCK – Free Report) and Medpace (MEDP Quick QuoteMEDP – Free Report) ."
- According to Zacks on Thursday, 12 October, "Some other top-ranked stocks in the broader medical space are DaVita Inc. (DVA Quick QuoteDVA – Free Report) , Quanterix (QTRX Quick QuoteQTRX – Free Report) and Align Technology (ALGN Quick QuoteALGN – Free Report) , each carrying a Zacks Rank #2."
- According to Zacks on Thursday, 12 October, "Some better-ranked stocks in the broader medical space are Cardinal Health (CAH Quick QuoteCAH – Free Report) , Haemonetics (HAE Quick QuoteHAE – Free Report) and Align Technology (ALGN Quick QuoteALGN – Free Report) , each carrying a Zacks Rank #2 (Buy) at present. "
4. Allianceberstein Holding L.P. Units (AB)
10.4% sales growth and 14.16% return on equity
AllianceBernstein Holding L.P. is publicly owned investment manager. The firm also provides research services to its clients. It provides its services to investment companies, pension and profit sharing plans, banks and thrift institutions, trusts, estates, government agencies, charitable organizations, individuals, corporations, and other business entities. The firm invests in public equity, fixed income, and alternative investment markets across the globe. It employs long/short strategy to make its investments. The firm conducts in-house research to make its investments. AllianceBernstein Holding L.P. was founded in 1987 and is based in New York, New York.
Earnings Per Share
As for profitability, Allianceberstein Holding L.P. Units has a trailing twelve months EPS of $2.26.
PE Ratio
Allianceberstein Holding L.P. Units has a trailing twelve months price to earnings ratio of 13.68. Meaning, the purchaser of the share is investing $13.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.16%.
5. Solar Capital Ltd. (SLRC)
9.5% sales growth and 5.85% return on equity
Solar Capital Ltd. is a business development company specializing in secured debt (first lien unitranche and second lien), subordinated (unsecured) debt, minority equity, and strategic income-oriented control equity investments in leveraged middle market companies. The fund invests in aerospace and defense; air freight & logistics; asset management; automotive; banking; beverage, food and tobacco; building products; buildings and real estate; broadcasting and entertainment; cargo transport; commercial services and supplies; communications equipment; chemicals, plastics and rubber; containers, packaging and glass; construction & engineering; diversified/conglomerate manufacturing; consumer Finance; distributors; diversified/conglomerate services; diversified financial services; diversified real estate sctivities; food products; Footwear; Education Services; diversified telecommunications services; electronics; farming and agriculture; finance; grocery; health care equipment and supplies; health care facilities; education and childcare; home and office furnishing, durable consumer products; hotels, motels, inns and gaming; insurance; restaurants, leisure, amusement, and entertainment; leisure equipment tolls and services, media, multiline retail, multi sector holdings; paper and forest products; personal products; professional services, research and consulting services, software; specialty retail; textiles apparel and luxury goods, thrifts and mortgage finance, trading companies and distributors, utilities, and wireless telecommunication services; industrial conglomerates; internet software and services, IT services, machinery; mining, steel, iron, and non precious metals; oil and gas; personal, food and miscellaneous services; printing and publishing; retail stores; telecommunications; textiles and leather; and utilities. It also invests in life sciences with focus on specialty pharmaceuticals, medical devices, biotech, health Care Providers and services; health Care technology, enabling technologies and tools. The fund primarily invests in United States. The fund's investments generally range between $5 million and $100 million. The fund invests in companies with revenues between $50 million and $1 billion and EBITDA between $15 million and $100 million. It invests in the form of senior secured loans, mezzanine loans, and equity securities. It may also seek investments in thinly traded public companies and also make secondary investments. The fund makes non-control equity investments. It primarily exits within three years of the initial capital commitment.
Earnings Per Share
As for profitability, Solar Capital Ltd. has a trailing twelve months EPS of $1.11.
PE Ratio
Solar Capital Ltd. has a trailing twelve months price to earnings ratio of 13.86. Meaning, the purchaser of the share is investing $13.86 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.85%.
Sales Growth
Solar Capital Ltd.’s sales growth is 23.2% for the current quarter and 9.5% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Sep 18, 2023, the estimated forward annual dividend rate is 1.64 and the estimated forward annual dividend yield is 10.65%.
Moving Average
Solar Capital Ltd.’s value is higher than its 50-day moving average of $15.20 and higher than its 200-day moving average of $14.76.
Yearly Top and Bottom Value
Solar Capital Ltd.’s stock is valued at $15.39 at 01:22 EST, under its 52-week high of $16.09 and way higher than its 52-week low of $12.08.
6. Ingredion Incorporated (INGR)
5.9% sales growth and 17.47% return on equity
Ingredion Incorporated, together with its subsidiaries, produces and sells starches and sweeteners for various industries. It operates through four segments: North America; South America; Asia Pacific; and Europe, Middle East, and Africa. The company offers sweetener products comprising glucose syrups, high maltose syrups, high fructose corn syrups, caramel colors, dextrose, polyols, maltodextrins, glucose and syrup solids, as well as food-grade and industrial starches, biomaterials, and nutrition ingredients. It also provides animal feed products; edible corn oil; refined corn oil to packers of cooking oil and to producers of margarine, salad dressings, shortening, mayonnaise, and other foods; and corn gluten feed used as protein feed for chickens, pet food, and aquaculture. The company's products are derived primarily from processing corn and other starch-based materials, such as tapioca, potato, and rice. It serves food, beverage, paper and corrugating products, brewing, pharmaceutical, textile, and personal care industries, as well as animal feed markets. The company was formerly known as Corn Products International, Inc. and changed its name to Ingredion Incorporated in June 2012. Ingredion Incorporated was founded in 1906 and is headquartered in Westchester, Illinois.
Earnings Per Share
As for profitability, Ingredion Incorporated has a trailing twelve months EPS of $8.57.
PE Ratio
Ingredion Incorporated has a trailing twelve months price to earnings ratio of 11.04. Meaning, the purchaser of the share is investing $11.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.47%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 12.1% and 16.4%, respectively.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Sep 28, 2023, the estimated forward annual dividend rate is 3.12 and the estimated forward annual dividend yield is 3.28%.
Moving Average
Ingredion Incorporated’s value is under its 50-day moving average of $100.85 and below its 200-day moving average of $102.89.
Sales Growth
Ingredion Incorporated’s sales growth is 5.1% for the ongoing quarter and 5.9% for the next.
7. Darling Ingredients (DAR)
5.8% sales growth and 19.87% return on equity
Darling Ingredients Inc. develops, produces, and sells natural ingredients from edible and inedible bio-nutrients. The company operates through three segments: Feed Ingredients, Food Ingredients, and Fuel Ingredients. It offers ingredients and customized specialty solutions for customers in the pharmaceutical, food, pet food, feed, industrial, fuel, bioenergy, and fertilizer industries. The company collects and transforms various animal by-product streams into useable and specialty ingredients, such as collagen, edible fats, feed-grade fats, animal proteins and meals, plasma, pet food ingredients, organic fertilizers, yellow grease, fuel feedstock, green energy, natural casings, and hides. It also recovers and converts used cooking oil and animal fats, and residual bakery products into valuable feed and fuel ingredients. In addition, the company provides environmental services, including grease trap collection and disposal services to food service establishments. It primarily operates under the Sonac, Dar Pro, Rothsay, Rousselot, CTH, Ecoson, and Rendac brand names in North America, Europe, China, South America, Australia, and internationally. The company was formerly known as Darling International Inc. and changed its name to Darling Ingredients Inc. in May 2014. Darling Ingredients Inc. was founded in 1882 and is headquartered in Irving, Texas.
Earnings Per Share
As for profitability, Darling Ingredients has a trailing twelve months EPS of $4.75.
PE Ratio
Darling Ingredients has a trailing twelve months price to earnings ratio of 9.89. Meaning, the purchaser of the share is investing $9.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.87%.
Sales Growth
Darling Ingredients’s sales growth is 12.9% for the current quarter and 5.8% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Darling Ingredients’s EBITDA is 30.55.
Yearly Top and Bottom Value
Darling Ingredients’s stock is valued at $46.98 at 01:22 EST, way below its 52-week high of $82.69 and above its 52-week low of $45.87.
Moving Average
Darling Ingredients’s value is way under its 50-day moving average of $59.96 and way below its 200-day moving average of $61.75.
8. First Business Financial Services (FBIZ)
5.5% sales growth and 14.66% return on equity
First Business Financial Services, Inc. operates as the bank holding company for First Business Bank that provides commercial banking products and services for small and medium-sized businesses, business owners, executives, professionals, and high net worth individuals. The company offers deposit products, such as non-interest-bearing transaction accounts, interest-bearing transaction accounts, money market accounts, time deposits, and certificates of deposit, as well as credit cards. It also provides loan products, including commercial real estate loans, commercial and industrial loans, small business administration loans, and direct financing leases, as well as consumer and other loans comprising home equity, first and second mortgage, and other personal loans for professional and executive clients. The company offers commercial lending, asset-based lending, equipment financing, accounts receivable financing, vendor financing, floorplan financing, treasury management services, and company retirement plans; trust and estate administration, financial planning, investment management, and private banking services; and investment portfolio administrative, asset-liability management, and asset-liability management process validation services for other financial institutions. First Business Financial Services, Inc. was founded in 1909 and is headquartered in Madison, Wisconsin.
Earnings Per Share
As for profitability, First Business Financial Services has a trailing twelve months EPS of $4.46.
PE Ratio
First Business Financial Services has a trailing twelve months price to earnings ratio of 6.62. Meaning, the purchaser of the share is investing $6.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.66%.
